Company news

Vectus Biosystems Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

FDA Pre-IND feedback for VB0004

November 15, 2026

Appointment of Prof Tamera Corte as Chief Clinical Advisor

November 8, 2026

Notification regarding unquoted securities - VBS

October 30, 2026

Quarterly Activities & Appendix 4C Cash Flow Reports

October 29, 2026

Quarterly Activities & Appendix 4C Cash Flow Reports

October 29, 2026

Results of 2026 AGM

October 27, 2026

2026 AGM Presentations

October 27, 2026

FDA Pre-IND Meeting Request Granted for VB0004

September 29, 2026

2026 Notice of Annual General Meeting & Proxy Form

September 25, 2026

2026 Corporate Governance Statement & Appendix 4G

September 18, 2026

Annual Report to shareholders

September 18, 2026

Date of 2026 Annual General Meeting

September 9, 2026

Change of Director's Interest Notice - MS

September 4, 2026

Cleansing Notice

September 2, 2026

Application for quotation of securities - VBS

September 2, 2026

Full Year Statutory Accounts

August 30, 2026

Preliminary Final Report

August 30, 2026

Cleansing Notice

July 29, 2026

Application for quotation of securities - VBS

July 29, 2026

Quarterly Activities & Appendix 4C Cash Flow Reports

July 28, 2026

Placement of Shares

May 22, 2026

Appointment of Dr Tara Speranza as CEO & CTO

May 7, 2026

VB4-P5 Renal Compound Transaction Settled

April 13, 2026

Half Year Report & Appendix 4D

February 26, 2026

Quarterly Activities & Appendix 4C Cash Flow Reports

January 30, 2026

Response to ASX Query Letter

November 11, 2025

Reinstatement to Quotation

October 17, 2025

VB4-P5 Renal Compound Transaction

October 17, 2025

Suspension from Quotation

October 17, 2025

Trading Halt

October 15, 2025

Pause in Trading

October 15, 2025

Preliminary Final Report

August 29, 2025

Agreement with C14 Consulting Group

August 30, 2024

Passing of Vectus CEO

May 20, 2024

Quarterly Activities/Appendix 4C Cash Flow Report

October 31, 2023

Preliminary Final Report - Appendix 4E

August 30, 2023

Half Yearly Report & Appendix 4D

February 24, 2023

Issue Of Shares Under Placement

December 1, 2022

Vectus - $3.5 million placement

November 22, 2022

Completion of Phase Ia for VB0004

September 14, 2022

Completion of Second M.A.D. Study for VB0004

August 8, 2022

Quarterly Activities Report & Appendix 4C

July 28, 2022

Completion of Final S.A.D. Study and First M.A.D. Study

May 25, 2022

Half Yearly Report and Appendix 4D

February 25, 2022

A Significant Milestone for VB0004

February 20, 2022

Chairman & CEO Address to Shareholders

January 24, 2022

Third S.A.D. Group Reviewed By Trial Safety Review Committee

November 28, 2021

Response to ASX Price and Volume Query

October 19, 2021

Update on Phase I Human Trial

September 6, 2021

Successful Completion of First Group in Phase I Human Trial

August 23, 2021

Older news releases →

Decks

The 5 newest of 11 decks. Every deck is listed under its year.